Foghorn Therapeutics Inc. Lease, Cost
Foghorn Therapeutics Inc. (FHTX) reported Lease, Cost of $1.28 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-06
- Foghorn Therapeutics Inc. lease, cost for the quarter ending 2026-06-30 was $1.28M, a 50.19% decline year-over-year.
- Foghorn Therapeutics Inc. lease, cost for the quarter ending 2026-03-31 was $1.28M, a 53.12% decline year-over-year.
- Foghorn Therapeutics Inc. lease, cost for the quarter ending 2025-12-31 was $1.68M, a 36.23% decline year-over-year.
- Foghorn Therapeutics Inc. lease, cost for the quarter ending 2025-09-30 was $1.71M, a 37.29% decline year-over-year.
- Foghorn Therapeutics Inc. lease, cost for fiscal 2025 was $8.71M, a 20.59% decline from fiscal 2024.
- Foghorn Therapeutics Inc. lease, cost for fiscal 2024 was $10.97M, a 4.89% increase from fiscal 2023.
- Foghorn Therapeutics Inc. lease, cost for fiscal 2023 was $10.46M, a 3.61% decline from fiscal 2022.
- Foghorn Therapeutics Inc. lease, cost for fiscal 2022 was $10.86M, a 3.99% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.28M 10-Q · filed 2026-08-06 | $2.57M 10-Q · filed 2026-08-06 | $4.25M derived: sum of 3 quarters · filed 2026-08-06 | $5.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.28M 10-Q · filed 2026-05-07 | $2.97M derived: sum of 2 quarters · filed 2026-05-07 | $4.68M derived: sum of 3 quarters · filed 2026-05-07 | $7.26M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $3.40M derived: sum of 2 quarters · filed 2026-03-11 | $5.97M derived: sum of 3 quarters · filed 2026-08-06 | $8.71M 10-K · filed 2026-03-11 |
| 2025-09-30 | $1.71M 10-Q · filed 2025-11-05 | $4.29M derived: sum of 2 quarters · filed 2026-08-06 | $7.03M 10-Q · filed 2025-11-05 | $9.67M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.58M 10-Q · filed 2026-08-06 | $5.32M 10-Q · filed 2026-08-06 | $7.96M derived: sum of 3 quarters · filed 2026-08-06 | $10.69M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.74M 10-Q · filed 2026-05-07 | $5.38M derived: sum of 2 quarters · filed 2026-05-07 | $8.11M derived: sum of 3 quarters · filed 2026-05-07 | $10.89M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $2.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $5.37M derived: sum of 2 quarters · filed 2026-03-11 | $8.15M derived: sum of 3 quarters · filed 2026-03-11 | $10.97M 10-K · filed 2026-03-11 |
| 2024-09-30 | $2.73M 10-Q · filed 2025-11-05 | $5.51M derived: sum of 2 quarters · filed 2025-11-05 | $8.34M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $2.78M 10-Q · filed 2025-08-05 | $5.61M 10-Q · filed 2025-08-05 | ||
| 2023-12-31 | $10.46M 10-K · filed 2025-03-06 | |||
| 2022-12-31 | $10.86M 10-K · filed 2024-03-07 | |||
| 2021-12-31 | $2.56M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $5.17M derived: sum of 2 quarters · filed 2023-03-09 | $7.79M derived: sum of 3 quarters · filed 2023-03-09 | $10.44M 10-K · filed 2023-03-09 |
| 2021-09-30 | $2.62M 10-Q · filed 2021-11-09 | $5.23M derived: sum of 2 quarters · filed 2021-11-09 | $7.88M 10-Q · filed 2021-11-09 | $10.38M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-06-30 | $2.61M 10-Q · filed 2021-08-10 | $5.26M 10-Q · filed 2021-08-10 | $7.76M derived: sum of 3 quarters · filed 2022-08-09 | $10.15M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $2.65M 10-Q · filed 2021-05-11 | $5.15M derived: sum of 2 quarters · filed 2022-08-09 | $7.54M derived: sum of 3 quarters · filed 2022-08-09 | $9.44M derived: sum of 4 quarters · filed 2022-08-09 |
| 2020-12-31 | $2.50M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-08-09 | $4.89M derived: sum of 2 quarters · filed 2022-08-09 | $6.79M derived: sum of 3 quarters · filed 2022-08-09 | $8.31M 10-K/A · filed 2022-08-09 |
| 2020-09-30 | $2.39M 10-Q · filed 2021-11-09 | $4.29M derived: sum of 2 quarters · filed 2021-11-09 | $5.81M 10-Q · filed 2021-11-09 | $6.38M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $1.90M 10-Q · filed 2021-08-10 | $3.42M 10-Q · filed 2021-08-10 | $4.00M derived: sum of 3 quarters · filed 2021-08-10 | $4.57M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $1.52M 10-Q · filed 2021-05-11 | $2.10M derived: sum of 2 quarters · filed 2021-05-11 | $2.67M derived: sum of 3 quarters · filed 2021-05-11 | |
| 2019-12-31 | $574.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $1.15M derived: sum of 2 quarters · filed 2021-03-18 | $2.28M 10-K · filed 2021-03-18 | |
| 2019-09-30 | $578.00K 10-Q · filed 2020-12-04 | $1.70M 10-Q · filed 2020-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |